These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 4156327)

  • 21. [Effects of a heterologous immune serum against bone marrow cells of the mouse].
    von Broen B
    Acta Biol Med Ger; 1974; 32(6):681-90. PubMed ID: 4153702
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of antilymphocyte sera on bone marrow allograft rejection.
    Riches AC; Thomas DB
    Exp Hematol; 1975 Jun; 3(3):169-80. PubMed ID: 1098919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro modification of donor bone marrow used to produce enhanced graft survival in antilymphocyte serum (ALS)-treated mice.
    Gozzo JJ; Wood ML; Pompei R; Monaco AP
    Transplant Proc; 1973 Mar; 5(1):853-6. PubMed ID: 4572148
    [No Abstract]   [Full Text] [Related]  

  • 24. Antilymphocytic antibodies and marrow transplantation. VI. Absence of immunosuppression in vivo after injection of monoclonal antibodies blocking graft-versus-host reactions and humoral antibody formation in vitro.
    Thierfelder S; Hoffmann-Fezer G; Rodt H; Doxiadis I; Eulitz M; Kummer U
    Transplantation; 1983 Mar; 35(3):249-54. PubMed ID: 6340277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute graft-versus-host reaction in mice. 3. Organ distribution of injected 51 chromium labeled lymphocytes.
    Silobrcić V; Vitale B; Susnjić M; Tomazic V; Basić I
    Exp Hematol; 1976 Mar; 4(2):103-13. PubMed ID: 4334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic effects of heterologous antilymphocytic sera.
    Jooste SV
    Lymphology; 1970 Jun; 3(2):79-103. PubMed ID: 4393251
    [No Abstract]   [Full Text] [Related]  

  • 27. An in vitro reaction between lymphoid cells and target fibroblastic cells: a possible model for in vivo rejection of haemopoietic allografts.
    Mayhew E; Bennett M
    Immunology; 1971 Jul; 21(1):123-36. PubMed ID: 4934136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of antilymphocyte serum and bone marrow for production of immunological tolerance and enhancement: review and recent experiments.
    Wood ML; Gozzo JJ; Monaco AP
    Transplant Proc; 1972 Dec; 4(4):523-9. PubMed ID: 4405146
    [No Abstract]   [Full Text] [Related]  

  • 29. The use of cell separation techniques and isantibody to host antigens in the treatent of severe combined immunodeficiency disease with HL-A incompatible maternal marrow.
    Gelfand EW; Phillips RA; Miller RG; McCulloch EA; Rosen FS
    Exp Hematol; 1974; 2(3):122-30. PubMed ID: 4156326
    [No Abstract]   [Full Text] [Related]  

  • 30. Regulation of the immune response. X. Antigen-antibody complex inactivation of cells involved in adoptive transfer.
    Sinclair NR; Lees RK; Abrahams S; Chan PL; Fagan G; Stiller CR
    J Immunol; 1974 Nov; 113(5):1493-500. PubMed ID: 4608468
    [No Abstract]   [Full Text] [Related]  

  • 31. Significance of antigen binding by T cells.
    Charreire J; Bach JF
    Transplant Proc; 1973 Dec; 5(4):1735-7. PubMed ID: 4130079
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of tritiated thymidine and 5-bromodeoxyuridine on development of immunologically competent lymphocytes.
    McGregor DD
    Immunology; 1969 Jan; 16(1):83-90. PubMed ID: 4890409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some comments on lymphocyte-mediated cytotoxicity and blocking serum activity in allograft tolerance.
    Hellström I; Hellström KE
    Johns Hopkins Med J Suppl; 1974; 3():301-5. PubMed ID: 4607384
    [No Abstract]   [Full Text] [Related]  

  • 34. GVHD suppression by incubation of bone marrow grafts with anti-T-cell globulin: effect in the canine model and application to clinical bone marrow transplantation.
    Rodt H; Kolb HJ; Netzel B; Rieder I; Janka G; Belohradsky B; Haas RJ; Thierfelder S
    Transplant Proc; 1979 Mar; 11(1):962-6. PubMed ID: 377731
    [No Abstract]   [Full Text] [Related]  

  • 35. [Use of heterologous antireceptor antibodies for specific reversal of acute homologous disease in mice].
    Nesterenko VG; Gruner Sh; Rubakova EI; Babadzhanov AS
    Biull Eksp Biol Med; 1980 Nov; 90(11):588-90. PubMed ID: 7192584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Graft-versus-host disease.
    Gatti RA; Kersey JH; Yunis EJ; Good RA
    Prog Clin Pathol; 1973; 5():1-18. PubMed ID: 4150104
    [No Abstract]   [Full Text] [Related]  

  • 37. Bone marrow transplantation: introduction.
    Mathé G; Oldham R
    Transplant Proc; 1974 Dec; 6(4):333-4. PubMed ID: 4155149
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk of donor lymphocyte infusions following allogeneic bone marrow transplantation.
    van Bekkum DW; Kinwel-Bohré EP
    Exp Hematol; 1997 Jun; 25(6):478-80. PubMed ID: 9197324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human marrow transplantation--current status.
    Buckner CD; Clift RA; Fefer A; Neiman P; Storb R; Thomas ED
    Prog Hematol; 1973; 8():299-324. PubMed ID: 4150971
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-CD4 IgG2a monoclonal antibody treatment prevents the expansion of T cells in the spleen during murine graft-vs-host disease.
    Noort WA; Benner R; Savelkoul HF
    Transplant Proc; 1995 Feb; 27(1):384-6. PubMed ID: 7879030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.